Infectious diseases

  • Fewer post-transplant CMV infections with novel antiviral prophylaxis

    on February 24th, 2017
    AT THE 2017 BMT TANDEM MEETINGS ORLANDO (FRONTLINE MEDICAL NEWS) – A first-in-class antiviral drug was safe and effective when used to prevent clinically significant cytomegalovirus infections in adults undergoing hematopoietic cell transplantation. At 24 weeks post-transplant, 38% (122/325) of th[...]
  • Infectious enteritis quadrupled short-term risk of IBS

    on February 24th, 2017
    FROM GASTROENTEROLOGY More than 10% of patients developed irritable bowel syndrome (IBS) within a year after infectious enteritis, which gave them a more than fourfold greater risk than that of controls, according to a systematic review and meta-analysis of 45 studies. “Protozoal and bacterial ent[...]
  • Zika vaccine development expected to last through 2020

    on February 24th, 2017
    FROM AN ACIP MEETING Progress continues to be made on creating a Zika vaccine, but taking any of the current candidates all the way through clinical trials and into production could take another few years, according to the latest information presented at a meeting of the Centers for Disease Control [...]
  • Following infection, semen is Zika’s last refuge

    on February 24th, 2017
    AT CROI SEATTLE (FRONTLINE MEDICAL NEWS) – Zika virus RNA lingered longer in semen than in any other body fluid but was cleared by 95% of men after 3 months, according to investigators from the Centers for Disease Control and Prevention. The findings support the agency’s recommendation that men [...]
  • Eliminating tap water consumption may prevent M. abscessus outbreaks

    on February 24th, 2017
    FROM CLINICAL INFECTIOUS DISEASES Abstaining from the consumption of tap water at health care facilities can dramatically reduce the risk of Mycobacterium abscessus infections among patients and staff, according to a new study published in Clinical Infectious Diseases. “Outbreaks of [M. abscessus][...]
  • Increased schizophrenia, affective disorder risks associated with infections

    on February 23rd, 2017
    FROM ACTA PSYCHIATRICA SCANDINAVICA Increased risks of schizophrenia and affective disorders were found to be associated with infections treated with anti-infective agents and with infections requiring hospitalization, a large-scale study shows. Researchers examined health records of all 1,015,447 i[...]
  • Preterm infants at higher risk of pertussis

    on February 23rd, 2017
    FROM PEDIATRIC INFECTIOUS DISEASE JOURNAL Preterm infants are at greater risk for pertussis than full-term infants, according to a population-based study from the Norwegian Institute of Public Health. Øystein Rolandsen Riise, MD, PhD, of the institute, and his colleagues identified all live births [...]
  • Unrestricted DAA access halved Dutch HCV incidence in HIV

    on February 23rd, 2017
    AT CROI SEATTLE (FRONTLINE MEDICAL NEWS) – New hepatitis C infections among HIV-positive men who have sex with men (MSM) were halved in the Netherlands by unrestricted access to direct-acting antivirals (DAAs), primarily ledipasvir/sofosbuvir tablets (Harvoni), according to Dutch investigators. Si[...]
  • Inactivated hepatitis A vaccine shows promise in 5-year study

    on February 23rd, 2017
    FROM HUMAN VACCINES & IMMUNOTHERAPEUTICS A single dose of an inactivated hepatitis A virus (HAV) vaccine resulted in high seropositive rates and antibody concentrations, persisting for at least 5 years in children, a study has shown. In October 2008, a team of investigators in China led by Zhilu[...]
  • ACIP approves minor changes to pediatric hepatitis B vaccine recommendations

    on February 22nd, 2017
    FROM AN ACIP MEETING Approval to changes of current recommendations for hepatitis B vaccinations for children were voted on by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP). The 14-member panel voted to approve changes to existing language, wh[...]
  • Antibody could replace conventional antiviral therapy in HIV

    on February 22nd, 2017
    AT CROI SEATTLE (FRONTLINE MEDICAL NEWS) – In a phase II trial, an antibody that targets domain 1 of the CD4 receptor maintained viral suppression among patients who had been taking combination antiretroviral therapy (cART). The study lasted up to 16 weeks, and no viral rebound was seen. In vitro [...]
  • Ibalizumab suppressed HIV-1 in multidrug-resistant patients

    on February 22nd, 2017
    AT CROI Seattle (FRONTLINE MEDICAL NEWS) – The antibody ibalizumab combined with an optimized background regimen maintained viral suppression out to 24 weeks, in an open-label extension study of patients with multidrug-resistant HIV-1 infections. The researchers had previously shown that the drug [...]
  • Small study: Drug combo achieves negative bacterial culture in all TB patients

    on February 22nd, 2017
    AT CROI SEATTLE (FRONTLINE MEDICAL NEWS) – An all-oral drug combination achieved negative bacterial culture in 100% of patients with extensively drug resistant (XDR) or multidrug resistant (MDR) tuberculosis at 4 months, according to a study. The drugs used were bedaquiline (400 mg once daily for [...]
Back to top